Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dronabinol + palmitoylethanolamide
- Development stage
- Phase 2
- Lead developer
- SciSparc
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Dronabinol + palmitoylethanolamide is a combination drug consisting of dronabinol, a synthetic form of delta-9-tetrahydrocannabinol (THC), and palmitoylethanolamide (PEA), an endogenous fatty acid amide. Dronabinol acts primarily as an agonist at cannabinoid receptor CB1 and CB2, modulating neurotransmitter release in the brain and providing antiemetic, appetite-stimulating, and neuroprotective effects. Palmitoylethanolamide exerts anti-inflammatory and analgesic actions mainly through activation of peroxisome proliferator-activated receptor alpha (PPAR-alpha) and modulation of G-protein-coupled receptor 55 (GPR55). The combination is being developed for neurological conditions such as agitation in Alzheimer's disease, Gilles de la Tourette's syndrome, and sleep apnea syndrome. It is designed to leverage both the central effects of THC/dronabinol on cannabinoid receptors and the peripheral anti-inflammatory properties of PEA[2][5].
- Other names
- SCI-110SCI110SCI 110
02
Targets
PPARA (Peroxisome proliferator-activated receptor alpha)CNR2 (Cannabinoid receptor type 2)GPR55 (G protein-coupled receptor 55)
Beyond the preview
Go deeper on dronabinol + palmitoylethanolamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dronabinol + palmitoylethanolamide.